I am pleased to share an important milestone for The Center for Functional Medicine: I have completed Dr. Dale Bredesen’s ReCODE 2.0 Advanced Clinical Training through Apollo Health. As described in our recent EIN Presswire announcement, this training brings a more structured precision-medicine framework to patients with cognitive concerns to Central Oregon and beyond.
For families watching memory, focus, language, or daily function decline, every moment matters. Cognitive decline is rarely explained by one laboratory value or one lifestyle habit. A careful evaluation must ask what is changing, how quickly it is changing, whether an urgent or treatable medical condition is present, and which modifiable factors may be adding to the burden.
This article explains what the certification means and how the ReCODE 2.0 framework fits with conventional cognitive care. If you are unsure whether your concerns deserve a closer look, you can begin with our free Cognitive Decline Risk Assessment Quiz. The quiz is an educational screening tool, not a diagnosis.
What Does ReCODE 2.0 Certification Mean?
For me, completing that program adds a defined cognitive-health framework to more than 30 years of clinical experience and my Institute for Functional Medicine certification. It offers a systematic way to organize complex history and examination findings, comprehensive lab data, genetics and cognitive testing into a meaningful care plan. The individualized care plan provides a roadmap to address all cognitive domains, diet and lifestyle factors. It also gives a logical framework of which domains need to be addressed first and the precise order to deliver the best outcomes.
What ReCODE 2.0 Does Not Do
While ReCODE 2.0 is a vast improvement over standard medical care, it is not an independent medical specialty or board certification. It does not guarantee that the treatment will be effective for all patients, nor does it guarantee that cognition will improve. Outcomes vary with diagnosis, disease stage, other health conditions, treatment fit, adherence, and many factors.
The most responsible use of ReCODE is as a personalized clinical framework that complements, rather than bypasses the medical standard of care, appropriate diagnostic workup and/or shared decision-making with a neurologist.
Why Cognitive Decline Requires a Wider Lens?
Memory complaints can arise from many conditions. Alzheimer’s disease is one possibility, but sleep apnea, medication effects, depression, thyroid disease, vitamin B12 deficiency, vascular disease, hearing loss, substance use, infection, head injury, and other neurological disorders can also affect thinking or function. More than one process may be present at the same time.
The Alzheimer’s Association’s current diagnostic-evaluation guideline emphasizes a structured, patient-centered evaluation that characterizes the level of impairment, all cognitive-behavioral symptoms (memory trouble, trouble word finding, depression etc.), and the likely underlying diseases or contributing conditions.
A functional medicine lens adds detailed attention to interconnected metabolic, inflammatory, nutritional, sleep, lifestyle, and environmental domains. The value lies in a deep investigation of the underlying root causes contributing to the disease process.
Root Cause Analysis for Cognitive Concerns
Unlike conventional treatments that target a single pathway, ReCODE 2.0 utilizes a Functional Medicine, root cause analysis to identify and address the dozens of underlying factors that drive Alzheimer’s disease. Dr. Bredesen’s research has identified at least 36 risk factors that cause or contribute to cognitive decline, including chronic inflammation, insulin resistance, hormone and nutrient imbalances, vascular changes, toxins, sleep problems and genetic risk such as APOE4 status.
The categories below are examples to evaluate, not a comprehensive checklist of all the reasons why an individual is declining.
Metabolic and Vascular Health
Blood pressure, diabetes, insulin resistance, lipid abnormalities, smoking, inactivity, and cardiovascular disease are relevant to brain health. The brain depends on steady blood flow and energy metabolism. Managing established vascular and metabolic conditions is part of good medical care and may also help reduce dementia risk. The World Health Organization risk-reduction guideline supports physical activity and appropriate management of hypertension and diabetes. This should be carefully evaluated and not ever condition or symptom warrants a drug. For example, many patients with hypertension can be better managed by giving magnesium and potassium and adding exercise, rather than putting them on a drug.
Sleep, Breathing, and Recovery
Poor sleep can worsen attention, mood, memory, glucose regulation, and blood pressure. A history of loud snoring, witnessed pauses in breathing, morning headaches, or excessive daytime sleepiness may justify evaluation for sleep apnea. Treating a diagnosed sleep disorder is essential in any comprehensive treatment focused on improving brain health and cognitive function; and overlooking it can sabotage the best laid plan.
Nutrition, Medications, and Medical Conditions
Nutrient deficiencies, thyroid disorders, anemia, medication side effects, alcohol or other substances can contribute to cognitive symptoms. Mood disorders can also affect brain function. A medication review and comprehensive laboratory evaluation often provide more actionable information than ordering several large specialty panels at the outset. Supplements are an essential part, particularly when micro and macro nutrient deficiencies exist. Your brain must absolutely have all the vitamins, minerals, micro and macro nutrients required for regeneration and repair for meaningful healing to take place. The quality, potency and purity of these nutrients are also very important when trying to reverse cognitive decline, as is proper kidney and liver function.
Inflammation, Oral Health, Gut Symptoms, and Exposures
Chronic inflammatory illness, dental problems and oral health, gastrointestinal symptoms, and specific occupational or environmental exposures all deserve attention. Some specialty tests used in functional medicine can provide important information about how certain environmental toxins or mold may be causing or contributing to cognitive decline. Chronic viral infections, Lyme, parasites, Leaky-gut syndrome and gut microbiome imbalance also need to be investigated.
Genetic Risk
APOE is one gene associated with Alzheimer’s risk, but it is not destiny and does not diagnose the disease. Genetic testing can have emotional, family, privacy, and insurance implications. Testing should be targeted and paired with informed counseling about what the result can and cannot tell you.
What Does the Research on ReCODE Show?
The evidence is encouraging but does not promise the reversal of Alzheimer’s or cognitive decline. ReCODE 2.0 is the best in class as far as established disease-modifying therapy, however, it is best implemented as early as possible during the MCI (Mild Cognitive Impairment) or early Alzheimer’s stage.
The 2022 Pilot Study and the 84 Percent Figure
A 2022 proof-of-concept study in the Journal of Alzheimer’s Disease. Twenty-five adults with mild cognitive impairment or early dementia and Montreal Cognitive Assessment scores of 19 or higher completed a nine-month personalized intervention. Twenty-one of 25 participants, or 84%, improved on an informant-rated change measure. The same proportion also improved on the computerized Neurocognitive Index.
Those results are notable, but the study was small and had no concurrent control group. Participants and clinicians knew they were receiving the intervention, and the multi-component design cannot show which elements produced benefit. The study excluded people with more advanced impairment, so its findings should not be generalized to every stage of dementia.
The 2026 Randomized Trial Preprint
A larger multicenter study registered as NCT05894954 randomized 73 people with mild cognitive impairment or early dementia to a personalized precision-medicine program or standard care. In the April 2026 preprint, the intervention group had greater gains on computerized measures of overall cognition, memory, executive function, and processing speed, along with improvements in several metabolic measures.
The randomized design is an important advance, yet the report has not completed peer review. It also excluded more advanced disease and did not confirm Alzheimer’s pathology with amyloid PET or cerebrospinal fluid testing. These findings should therefore be described as promising and preliminary.
What Does a Functional Medicine Approach Look Like?
A responsible functional medicine evaluation begins with the person, not a protocol. It combines a detailed history with appropriate conventional assessment, then uses additional testing selectively when the result is likely to change care.
- Clarify the concern. When did changes begin? Are they stable, gradual, or rapid? Which tasks are affected? A family member or care partner can often provide essential context.
- Review health and function. Sleep, movement, nutrition, mood, hearing, vision, medications, cardiovascular history, metabolic health, infections, head injuries, substance exposure, and daily independence all matter.
- Complete appropriate standard evaluation. Depending on the presentation, this may include a physical and neurological examination, validated cognitive testing, routine laboratory work, medication review, brain imaging, neuropsychological testing, or referral to neurology or another specialist.
- Consider targeted advanced testing. Metabolic markers, sleep studies, selected nutritional tests, genetic testing, or other specialty evaluations may be useful when there is a specific rationale. Not every patient needs every test.
- Build and monitor an individualized plan. Plans may address diagnosed medical conditions, physical activity, food quality, sleep, stress, social connection, hearing, oral health, safety, and caregiver support. Recommendations should be feasible, coordinated, and adjusted according to objective findings and response.
This approach may sit alongside medications, specialist care, rehabilitation, or clinical-trial participation. Patients should not stop or change prescribed medication without consulting the prescribing clinician.
Who May Benefit From an Earlier Conversation?
An evaluation may be appropriate when you or someone close to you notices persistent changes in memory, word finding, attention, judgment, navigation, mood, or the ability to manage familiar tasks. It may also be reasonable for people with diagnosed mild cognitive impairment, early-stage dementia, a strong family history, or questions about modifiable risk factors.
Early evaluation does not assume Alzheimer’s disease. It creates an opportunity to identify reversible contributors, establish a baseline, clarify the diagnosis, discuss available treatment options, and plan support while the person can participate fully in decisions.
Actionable Next Steps
- Write down specific examples. Note what changed, when it started, how often it happens, and whether it affects safety, finances, driving, medication use, work, or daily routines.
- Bring a trusted observer. A spouse, relative, or close friend may notice patterns that are difficult to recognize from inside the experience.
- Request a comprehensive clinical evaluation. A quiz or online test cannot distinguish Alzheimer’s disease from sleep, medication, metabolic, psychiatric, or other neurological causes.
- Support the foundations now. Engage in regular movement, address blood pressure and diabetes, restorative sleep, hearing, smoking cessation, social connection, and a nutrient-dense eating pattern are all within your control. The CDC overview of modifiable dementia risks is a useful starting point.
- Use our quiz as a conversation starter. Take the two-minute Cognitive Decline Risk Assessment and bring the result, along with your questions.
When Is Cognitive Change Urgent?
Sudden confusion, new weakness or numbness, facial droop, trouble speaking, severe headache, loss of consciousness, a seizure, abrupt behavior change, or an immediate safety concern requires urgent medical assessment. Call emergency services rather than waiting for a routine visit.
A More Informed Starting Point for Central Oregon Families
ReCODE 2.0 certification gives our practice advanced tools for organizing and investigating cognitive concerns, along with a proven framework to address modifiable risk factors. It does not change the need for careful diagnosis, honest discussion of uncertainty, or collaboration with the patient’s existing medical team. It does strengthen our ability to ask a broader set of questions and translate those findings into a structured plan.
If you are concerned about your memory or a loved one’s cognitive health, do not wait for a crisis to begin the conversation. Read the full press release, explore our Alzheimer’s and Bredesen ReCODE program, or start with our Cognitive Decline Risk Assessment Quiz. The next step is a thoughtful evaluation of what may be happening and what evidence-based, individualized actions deserve consideration.
Educational disclaimer: This article is for general education and does not provide a diagnosis or individualized medical advice. Cognitive symptoms warrant evaluation by a qualified healthcare professional. Treatment decisions should be made with clinicians who know your medical history and scope of care. However, many physicians are not well versed in treatment options that are not pharmaceutically based.
